약물감시 및 의약품 안전성 소프트웨어 시장 규모, 점유율, 동향 분석 보고서 : 기능성별, 전개별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Pharmacovigilance And Drug Safety Software Market Size, Share & Trends Analysis Report By Functionality, By Deployment, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,656,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,111,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,021,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

약물감시 및 의약품 안전성 소프트웨어 시장 요약

세계의 약물감시 및 의약품 안전성 소프트웨어 시장 규모는 2024년에 2억 1,096만 달러로 평가되었으며, 2033년까지 3억 8,874만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 7.1%의 연평균 성장률을 보일 것으로 예상됩니다. 데이터 가용성 확대, 생성된 데이터 처리 및 인사이트 도출의 필요성, 엄격한 보고 규범 및 기준, 주요 기업의 소프트웨어 업그레이드 증가 등이 이 시장의 주요 촉진요인으로 작용하고 있습니다.

액센츄어의 'INTIENT Pharmacovigilance'는 의약품 안전성 모니터링 데이터 수집 및 관리를 지원하는 종합적인 제품군입니다. 이 플랫폼은 잠재적인 컴플라이언스 문제 및 새로운 트렌드 파악, 부작용 보고를 가능하게 합니다. 약물유해반응(ADR)과 약물오남용 발생률의 증가는 업계 성장의 주요 촉진요인입니다. 약물 치료의 복잡성과 다약제 병용(polypharmacy)이 증가함에 따라 의료 시스템은 환자 안전을 저해하고 입원율을 높이는 부작용의 위험에 직면해 있습니다. Springer Nature에 발표된 논문에 따르면, 2018년 6월부터 2021년 5월까지 급성 내과 질환으로 입원한 5,707명의 연속 환자 중 ADR로 인한 응급입원 비율은 5.0%(95% CI 4.5-5.6%)로 보고됐습니다. 이러한 결과는 실시간 모니터링과 자동 보고 시스템을 통해 약물 관련 위험을 효율적으로 감지, 분석, 예방할 수 있는 첨단 약물감시 솔루션의 필요성을 강력하게 시사하고 있습니다.

또한, 유럽의약품청(EMA), 미국 식품의약국(FDA) 등 정부 기관의 안전 가이드라인 준수에 대한 압박이 커지면서 파마코비지런스의 도입 확대에 기여하고 있습니다. 많은 제약회사들이 운영비용을 절감하기 위해 약물감시 활동의 아웃소싱으로 전환하고 있습니다. 제조업체는 완전 통합형 제약회사에서 서비스 제공자와의 협력을 통한 비용 분담으로 점차 전환하고 있습니다. 외부에 위탁하는 서비스는 의료 문서 작성 및 임상시험 데이터 수집부터 의료 보고 및 기타 PV 서비스까지 다양합니다. 아웃소싱은 내부 리소스의 유연성 향상, 타임라인 개선, 그리고 더 나은 성과로 이어집니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향 및 범위

• 시장 동향 전망
• 시장 역학
• 사업 환경 분석
  • Porter's Five Forces 분석
  • PESTLE 분석

제4장 약물감시 및 의약품 안전성 소프트웨어 시장 : 전개별 추정·동향 분석

• 전개별 대시보드
• 전개별 시장 점유율 변동 분석(2024년 및 2033년)
• 전개별 시장 규모 및 예측 및 동향 분석(2021년에서 2033년)
• 온프레미스
• 온디맨드

제5장 약물감시 및 의약품 안전성 소프트웨어 시장 : 기능성별 추정·동향 분석

• 기능성별 대시보드
• 기능성별 시장 점유율 변동 분석(2024년 및 2033년)
• 기능성별 시장 규모 및 예측 및 동향 분석(2021-2033년)
• 증례 데이터 수집과 관리
• 유해 사례 보고와 분석
• 신호 검출 및 기타 안전성 리스크 평가

제6장 약물감시 및 의약품 안전성 소프트웨어 시장 : 최종 용도별 추정·동향 분석

• 최종 용도별 시장 점유율 변동 분석(2024년 및 2033년)
• 최종 용도별 시장 규모 및 예측 및 동향 분석(2021-2033년)
• 헬스케어 기업(제약회사 및 바이오테크놀러지 기업)
• CRO/BPO 또는 PV 서비스 프로바이더(외부 위탁시)
• 기타

제7장 약물감시 및 의약품 안전성 소프트웨어 시장 : 지역별 추정·동향 분석

• 지역별 시장 대시보드
• 지역별 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 진출 기업 개요
• 기업 시장 상황 분석/기업 점유율 분석(2024년)
• 기업 분류
• 전략 매핑
• 기업 개요/리스트
  • Oracle(Cerner)
  • Accenture
  • IBM Corporation
  • ITClinical
  • UBC(United BioSource Corporation)
  • Ab Cube
  • Ennov
  • EXTEDO
  • Veeva Systems
  • IQVIA
  • Sarjen Systems Pvt. Ltd.
  • Flex Databases
  • Tepsivo Oy
  • ArisGlobal
  • EVERSANA

KSM

영문 목차

영문목차

Pharmacovigilance And Drug Safety Software Market Summary

The global pharmacovigilance and drug safety software market size was valued at USD 210.96 million in 2024 and is projected to reach USD 388.74 million by 2033, growing at a CAGR of 7.1% from 2025 to 2033. The growing availability of data, the need to process & derive insights from the generated data, stringent reporting norms & standards, and increasing software upgrades by key companies are some of the key drivers of this market.

INTIENT Pharmacovigilance by Accenture is a comprehensive product suite that helps in the collection and management of a full spectrum of pharmacovigilance data. The platform also enables users to understand potential compliance issues and emerging trends and report on adverse events. The rising incidence of adverse drug reactions (ADRs) and medication errors is a key factor driving the growth of the industry. As drug therapies become more complex and polypharmacy increases, healthcare systems face greater risks of adverse events that compromise patient safety and increase hospitalizations. According to an article published by Springer Nature, the proportion of urgent hospitalizations caused by ADRs was reported as 5.0% (95% CI 4.5-5.6%) among 5,707 consecutive patients hospitalized for acute medical illnesses between June 2018 and May 2021. Such findings highlight the critical need for advanced pharmacovigilance solutions that can efficiently detect, analyze, and prevent drug-related risks through real-time monitoring and automated reporting systems.

Moreover, increasing pressure to follow safety guidelines set by government authorities such as the European Medicines Agency and the U.S. FDA is contributing to the growing adoption of pharmacovigilance systems. Many pharmaceutical companies are moving toward outsourcing pharmacovigilance activities to curb operational costs. Manufacturers are gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers. Services outsourced range from medical writing and clinical trial data collection to medical reporting and other PV services. Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes.

Gobal Pharmacovigilance And Drug Safety Software Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacovigilance and drug safety software market report based on deployment, functionality, end use, and regions.

• Deployment Outlook (Revenue, USD Million, 2021 - 2033)
• On Premise
• On Demand
• Functionality Outlook (Revenue, USD Million, 2021 - 2033)
• Case data collection and management
• Adverse event reporting and analysis
• Signal detection and other safety risk assessment
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
• CROs/BPOs or PV service providers when outsourced.
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Deployment
  • 1.2.2. Functionality
  • 1.2.3. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing drug consumption and drug development rates
    • 3.2.1.2. Increasing incidence of ADR and drug toxicity
    • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
    • 3.2.1.4. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
    • 3.2.1.5. Increasing regulatory burden on manufacturers
    • 3.2.1.6. Introduction of technologically advanced software services
    • 3.2.1.7. Rising investment on R&D by healthcare companies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of skilled professionals
    • 3.2.2.2. Expensive technology for small and mid-sized Players
    • 3.2.2.3. Lack of Recognition
    • 3.2.2.4. Scarcity of integration standards
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. PV Services Pricing Models
    • 3.2.5.1. Drug Safety Budget Allocation By Activities
    • 3.2.5.2. By Development Phase
    • 3.2.5.3. By Therapeutic Area
    • 3.2.5.4. Pricing Level
      • 3.2.5.4.1.Project management
      • 3.2.5.4.2.Case processing
      • 3.2.5.4.3.ADR Reporting
      • 3.2.5.4.4.Medical writing
      • 3.2.5.4.5.Drug safety management
  • 3.2.6. Technology Overview
  • 3.2.7. Case Studies
  • 3.2.8. Inflation's Impact on the Overall PV and Drug Safety Software Market
  • 3.2.9. Market Competitive Factors and Strategies
  • 3.2.10. Healthcare Companies Using PV Services
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Pharmacovigilance and Drug Safety Software Market: Deployment Estimates & Trend Analysis

• 4.1. Deployment Dashboard
• 4.2. Deployment Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Deployment, 2021 to 2033 (USD Million)
• 4.4. On-Premise
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. On-Demand
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharmacovigilance and Drug Safety Software Market: Functionality Estimates & Trend Analysis

• 5.1. Functionality Dashboard
• 5.2. Functionality Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Functionality, 2021 to 2033 (USD Million)
• 5.4. Case data collection and management
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Adverse event reporting and analysis
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Signal detection and other safety risk assessment
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharmacovigilance and Drug Safety Software Market: End Use Estimates & Trend Analysis

• 6.1. End use Segment Dashboard
• 6.2. End use Market Share Movement Analysis, 2024 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. CROs/BPOs or PV service providers when outsourced.
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pharmacovigilance and Drug Safety Software Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market: Key Takeaways
• 7.3. North America
  • 7.3.1. North America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamic
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive insights
    • 7.3.2.4. U.S. Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamic
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive insights
    • 7.3.3.4. Canada Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamic
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Competitive insights
    • 7.3.4.4. Mexico Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. Germany Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. UK Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. France Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamic
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive insights
    • 7.4.5.4. Italy Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamic
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive insights
    • 7.4.6.4. Spain Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamic
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive insights
    • 7.4.7.4. Denmark Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamic
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive insights
    • 7.4.8.4. Sweden Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamic
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive insights
    • 7.4.9.4. Norway Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. Japan Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. China Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. India Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. South Korea Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Australia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Thailand Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Pharmacovigilance and Drug Safety Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Brazil Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. Argentina Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. South Africa Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Saudi Arabia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamic
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive insights
    • 7.7.4.4. UAE Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamic
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive insights
    • 7.7.5.4. Kuwait Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis/Company Market Share Analysis, (2024)
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Oracle (Cerner)
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. Accenture
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. IBM Corporation
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. ITClinical
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. UBC (United BioSource Corporation)
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Ab Cube
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Ennov
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. EXTEDO
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Veeva Systems
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. IQVIA
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Sarjen Systems Pvt. Ltd.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Flex Databases
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Tepsivo Oy
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. ArisGlobal
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. EVERSANA
    • 8.5.15.1. Overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product benchmarking
    • 8.5.15.4. Strategic initiatives

관련자료